Patents by Inventor Christine A. Klein
Christine A. Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944742Abstract: A method for veterinary administration of medication to an animal, particularly a horse, is disclosed. The method involves inserting a capsule containing the medication, which is a liquid formulation, into a device connected to a tubular chamber. An atomizer is activated to atomize the medication, producing atomized medication. Before administration, a force is applied to a mask placed over the animal's muzzle, connected to the chamber. The atomized medication is then delivered to the animal. The liquid formulation, in some instances, comprises cells, cellular byproducts, or cell-derived products such as stem cells or products from human mesenchymal stem cells. This formulation may lack preservatives and may encompass peptides, proteins, growth factors, cytokines, exosomes, and extracellular vesicles. The delivery mechanism may involve deflating an air bladder to convey the atomized medication.Type: GrantFiled: September 26, 2023Date of Patent: April 2, 2024Inventors: Pradeep Albert, Christine Nichols, David J. Condron, Brian Artze, Fadi Saba, Jesse Klein, Vijay Vad
-
Publication number: 20240092856Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.Type: ApplicationFiled: March 8, 2022Publication date: March 21, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
-
Patent number: 11925748Abstract: The invention pertains to a capsule system for use with a medical device designed to administer atomized medication to patients. The system features a chamber containing the medication and an atomizer at a lower end for efficient drug delivery. Notably, the system incorporates a fluid sensor and electrical contacts to ensure proper operation and medication delivery. The capsule's design includes a housing with an asymmetrical transverse cross-sectional shape for unique fitting, and a tapered wall to direct medication towards the atomizer. The capsule may also connect to an external container or include a stopper for refilling medication. A specific embodiment features two chambers with a rupturing element to facilitate medication transfer. Another embodiment includes a removable container, like a vial, within the first chamber. This novel system provides improvements in accuracy, versatility, and user-friendliness, overcoming limitations in prior art.Type: GrantFiled: August 15, 2023Date of Patent: March 12, 2024Inventors: Pradeep Albert, Christine Nichols, David J. Condron, Brian Artze, Fadi Saba, Jesse Klein, Vijay Vad
-
Publication number: 20120225845Abstract: The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.Type: ApplicationFiled: May 4, 2012Publication date: September 6, 2012Applicant: Myrexis, Inc.Inventors: Christine Klein, Andrew D. Gassman, Leena Bhoite, John Manfredi
-
Publication number: 20120065241Abstract: Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.Type: ApplicationFiled: November 15, 2011Publication date: March 15, 2012Applicant: Myrexis, Inc.Inventors: Christine Klein, Andrew Gassman, Leena Bhoite, John Manfredi
-
Publication number: 20110266315Abstract: There is disclosed a portable gum container, comprising a body. The body has a chewing gum holder, a sheet material dispenser, and a waste receptacle. The chewing gum holder is for holding chewing gum. The sheet material dispenser is for dispensing sheet material sized and shaped for wrapping about a piece of spent chewing gum. The waste receptacle is sized and shaped to contain the wrapped spent piece of chewing gum. Also disclosed is a portable gum container, comprising a body having a chewing gum holder, a waste receptacle and at least one piece of sheet material associated with the body for wrapping about a piece of spent chewing gum.Type: ApplicationFiled: July 12, 2011Publication date: November 3, 2011Inventor: Marianne Christine Klein
-
Patent number: 8006860Abstract: There is disclosed a portable gum container, comprising a body. The body has a chewing gum holder, a sheet material dispenser, and a waste receptacle. The chewing gum holder is for holding chewing gum. The sheet material dispenser is for dispensing sheet material sized and shaped for wrapping about a piece of spent chewing gum. The waste receptacle is sized and shaped to contain the wrapped spent piece of chewing gum. Also disclosed is a portable gum container, comprising a body having a chewing gum holder, a waste receptacle and at least one piece of sheet material associated with the body for wrapping about a piece of spent chewing gum.Type: GrantFiled: December 14, 2007Date of Patent: August 30, 2011Inventor: Marianne Christine Klein
-
Patent number: 7611854Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.Type: GrantFiled: June 18, 2003Date of Patent: November 3, 2009Assignee: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
-
Publication number: 20090253768Abstract: Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.Type: ApplicationFiled: March 9, 2009Publication date: October 8, 2009Applicant: Myriad Genetics, IncorporatedInventors: Christine Klein, Andrew Gassman, Leena Bhoite, John Manfredi
-
Publication number: 20090151115Abstract: There is disclosed a portable gum container, comprising a body. The body has a chewing gum holder, a sheet material dispenser, and a waste receptacle. The chewing gum holder is for holding chewing gum. The sheet material dispenser is for dispensing sheet material sized and shaped for wrapping about a piece of spent chewing gum. The waste receptacle is sized and shaped to contain the wrapped spent piece of chewing gum. Also disclosed is a portable gum container, comprising a body having a chewing gum holder, a waste receptacle and at least one piece of sheet material associated with the body for wrapping about a piece of spent chewing gum.Type: ApplicationFiled: December 14, 2007Publication date: June 18, 2009Inventor: Marianne Christine Klein
-
Publication number: 20090099179Abstract: The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.Type: ApplicationFiled: April 4, 2007Publication date: April 16, 2009Applicant: MYRIAD GENETICS, INCORPORATEDInventors: Christine Klein, Andrew D. Gassman, Leena Bhoite, John Manfredi
-
Publication number: 20080268475Abstract: The present invention pertains to novel yeast cells which are useful for the expression of heterologous G protein coupled receptors. The yeast cells of the present invention can be used in screening assays which can be used to screen for modulators of G protein coupled receptors. Specifically, the invention provides novel yeast cells which express a heterologous G protein coupled receptor and mutant and/or chimeric G protein subunit molecules which serve to functionally integrate the heterologous into the pheromone signaling pathway of the yeast cell. The invention also provides for the expression of heterologous G protein coupled receptors which are functionally integrated into the yeast cell membrane using a yeast ? factor leader sequence. Drug discovery assays using the subject yeast cells are also provided.Type: ApplicationFiled: April 21, 2008Publication date: October 30, 2008Applicant: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, James R. Broach, John P. Manfredi, Jeremy I. Paul, Joshua Trueheart, Christine A. Klein, Andrew J.M. Murphy
-
Patent number: 7416881Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.Type: GrantFiled: April 5, 1999Date of Patent: August 26, 2008Assignee: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
-
Patent number: 7361498Abstract: The present invention pertains to novel yeast cells which are useful for the expression of heterologous G protein coupled receptors. The yeast cells of the present invention can be used in screening assays which can be used to screen for modulators of G protein coupled receptors. Specifically, the invention provides novel yeast cells which express a heterologous G protein coupled receptor and mutant and/or chimeric G protein subunit molecules which serve to functionally integrate the heterologous into the pheromone signaling pathway of the yeast cell. The invention also provides for the expression of heterologous G protein coupled receptors which are functionally integrated into the yeast cell membrane using a yeast ? factor leader sequence. Drug discovery assays using the subject yeast cells are also provided.Type: GrantFiled: October 15, 2004Date of Patent: April 22, 2008Assignee: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, James R. Broach, John P. Manfredi, Jeremy I. Paul, Joshua Trueheart, Christine A. Klein, Andrew J. M. Murphy
-
Patent number: 7319009Abstract: The present invention makes available rapid, effective assays for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assays enable rapid screening of large numbers of polypeptides in a library to identify those polypeptides which induce or antagonize receptor bioactivity. The subject assays are particularly amenable for identifying agonists and antagonists for orphan receptors. In particular the present invention makes available novel ligand agonists of human formyl peptide receptor like-1 (FPRL-1) receptors. These novel ligand agonists are used in the assays of the invention to identify modulators of FPRL-1 receptor.Type: GrantFiled: October 22, 2002Date of Patent: January 15, 2008Assignee: Cadus Technologies, Inc.Inventors: Christine A. Klein, Andrew J. Murphy, Jeremy Paul
-
Patent number: 7250263Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.Type: GrantFiled: January 5, 2004Date of Patent: July 31, 2007Assignee: Cadus Technologies, Inc.Inventors: Christine A. Klein, Andrew J. M. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
-
Patent number: 7235648Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.Type: GrantFiled: February 26, 1999Date of Patent: June 26, 2007Assignee: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
-
Patent number: 7122305Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.Type: GrantFiled: December 21, 2000Date of Patent: October 17, 2006Assignee: Cadus Technologies, Inc.Inventors: Christine A. Klein, Andrew J. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
-
Patent number: 7105309Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.Type: GrantFiled: October 1, 2002Date of Patent: September 12, 2006Assignee: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, James R. Broach, John P. Manfredi, Christine A. Klein, Andrew J. M. Murphy, Jeremy I. Paul, Joshua Trueheart
-
Publication number: 20050202403Abstract: The present invention pertains to novel yeast cells which are useful for the expression of heterologous G protein coupled receptors. The yeast cells of the present invention can be used in screening assays which can be used to screen for modulators of G protein coupled receptors. Specifically, the invention provides novel yeast cells which express a heterologous G protein coupled receptor and mutant and/or chimeric G protein subunit molecules which serve to functionally integrate the heterologous into the pheromone signaling pathway of the yeast cell. The invention also provides for the expression of heterologous G protein coupled receptors which are functionally integrated into the yeast cell membrane using a yeast a factor leader sequence. Drug discovery assays using the subject yeast cells are also provided.Type: ApplicationFiled: October 15, 2004Publication date: September 15, 2005Applicant: Cadus Technologies, Inc.Inventors: Dana Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart, Christine Klein, Andrew Murphy